Lipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2

Laboratory of Metabolic Disorders and Alternative Medicine, Department of Molecular Biosciences and Bioengineering, College of Tropical Agriculture and Human Resources, Room 415H, East-West Road, Honolulu, HI 96822, USA.
British Journal of Pharmacology (Impact Factor: 4.84). 09/2006; 148(8):1156-64. DOI: 10.1038/sj.bjp.0706821
Source: PubMed

ABSTRACT 1. Hyperlipidemic effects of HIV-1-protease inhibitors (PI) are associated with increased hepatic production of triglyceride (TG)-rich lipoproteins, rather than lipoprotein clearance. PI are known to increase apolipoprotein B (apoB) secretion, apoC-III mRNA expression and decrease apoA-1 secretion. Nutritional therapy remains an important strategy to manage PI-associated hyperlipidemia. 2. This study investigated the in vitro efficacy of Asian vegetable, Momordica charantia or bitter melon (BM) to ameliorate PI-associated apoB and lipid abnormalities in HepG2 cells. 3. Our study demonstrates that bitter melon juice (BMJ) significantly reduced apoB secretion and apoC-III mRNA expression and normalized apoA-I expression in PI-treated HepG2 cells. BMJ also significantly reduced cellular TG and microsomal TG transfer protein, suggesting that lipid bioavailability and lipidation of apoB assembly may play a role in decreased apoB secretion. 4. Identifying molecular targets of BM may offer alternative dietary strategies to decrease PI-associated hyperlipidemia and improve quality of life among HIV-1-infected patients.

Download full-text


Available from: Vivek Nerurkar, Sep 01, 2015
1 Follower
11 Reads
  • Source
    • "Bitter melon (Momordica charantia) is widely cultivated in Asia, Africa, and South America, and extensively used in folk medicines as a remedy for diabetes, specifically in South East Asia. Animal studies have employed either fresh bitter melon extract (BME) or crude organic fractions to evaluate its beneficial effects on glucose metabolism and on plasma and hepatic lipids [4], [5]. We have previously shown that BME (without seeds) treatment of human cancer cells induced cell cycle arrest by altering critical signaling molecules and impairing cell growth [6], [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Head and neck squamous cell carcinoma (HNSCC) remains difficult to treat, and despite of advances in treatment, the overall survival rate has only modestly improved over the past several years. Thus, there is an urgent need for additional therapeutic modalities. We hypothesized that treatment of HNSCC cells with a dietary product such as bitter melon extract (BME) modulates multiple signaling pathways and regresses HNSCC tumor growth in a preclinical model. We observed a reduced cell proliferation in HNSCC cell lines. The mechanistic studies reveal that treatment of BME in HNSCC cells inhibited c-Met signaling pathway. We also observed that BME treatment in HNSCC reduced phosphoStat3, c-myc and Mcl-1 expression, downstream signaling molecules of c-Met. Furthermore, BME treatment in HNSCC cells modulated the expression of key cell cycle progression molecules leading to halted cell growth. Finally, BME feeding in mice bearing HNSCC xenograft tumor resulted in an inhibition of tumor growth and c-Met expression. Together, our results suggested that BME treatment in HNSCC cells modulates multiple signaling pathways and may have therapeutic potential for treating HNSCC.
    PLoS ONE 10/2013; 8(10):e78006. DOI:10.1371/journal.pone.0078006 · 3.23 Impact Factor
  • Source
    • "In recent years, a number of chemical components that possess medicinal attributes have been isolated from bitter gourd, such as c-momorcharin, which inactivates ribosome function (Feng et al. 1990; Leung et al. 1997) and stimulates MAP30 (Momordica anti-HIV protein) production, which, in turn, simultaneously suppresses HIV (human immunodeficiency virus) activity (Lee et al. 1990, 1995). Interestingly, momordicoside A and B present in bitter gourd inhibit tumor growth (Okabe et al. 1980), and several bitter gourd phytochemicals have in vitro antiviral activity against viruses including Epstein-Barr, herpes, and HIV viruses (Takemoto 1983; Lee et al. 1990; Nerurkar et al. 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: This chapter contains sections titled: Introduction Botany Horticulture Breeding Conclusions Literature Cited
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Momordica charantia Linn. which has been used mainly for edible purposes at different countries of the world including South East Asia and has also been extensively used in traditional medicines for the cure of various ailments. M. charantia belongs to the cucurbitaceae family. Extensive research has been carried out on the fruit, leaves, and seeds of the plant. Most importantly, all these research works have shown its efficacy on various cancer cell lines like lymphoid leukemia, lymphoma, choriocarcinoma, melanoma, breast cancer, skin tumor, prostatic cancer, squamous carcinoma of tongue and larynx, human bladder carcinomas and on Hodgkin's disease. Clinical reports of some research on the use of M. charantia in diabetes and cancer patients showed promising results. The main active constituents of M. charantia are cucurbitane type triterpenoids which have some potent biological and pharmacological activities including antidiabetic, anti-obesity, anticancer, anti-HIV, anti-feedant and anti-oviposition activities. Since in the early 1960's the constituents of M. charantia have been investigated and several classes of secondary metabolites including cucurbitane-type triterpenoids, glycosides and phenolic compounds have been isolated and their structures were determined. This review summarizes the previous and current information regarding phytochemical constituents of M. charantia and their pharmacological effects that provide the scope for future research in this aspect.
Show more